Cardiac Drug Development Guide

  • Michael K. Pugsley

Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Table of contents

  1. Front Matter
    Pages i-x
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. Michael K. Pugsley
      Pages 3-24
  3. Novel Molecular Targets for Cardiac Drug Development

    1. Front Matter
      Pages 25-25
    2. Elizabeth Roth, Laszlo Hejjel
      Pages 47-66
    3. Tanya Ravingerova, Miroslav Barancik, Monika Strniskova
      Pages 67-86
    4. Melanie B. Smith, David J. Lefer
      Pages 87-105
    5. Morris Karmazyn
      Pages 123-139
    6. Mariarosaria Bucci, Inmaculada Posadas Mayo, Giuseppe Cirino
      Pages 141-160
  4. Functional Endpoints Evaluating Cardiac Drug Activity

    1. Front Matter
      Pages 161-161
    2. J. Christian Hesketh, David Fedida
      Pages 163-174
    3. Michael J. A. Walker, Leon J. Guppy
      Pages 175-201
    4. Hugh Clements-Jewery, Michael J. Curtis
      Pages 203-225
    5. László Szekeres, James Parratt
      Pages 271-293
  5. Clinical Aspects in Cardiac Drug Development

    1. Front Matter
      Pages 295-295
    2. Jeffrey A. Towbin, Matteo Vatta, Hua Li, Neil E. Bowles
      Pages 317-349
    3. Hendrik T. Tevaearai, Andrea D. Eckhart, Walter J. Koch
      Pages 351-364
    4. Paul J. Williams, Amit Desai, Ene Ette
      Pages 365-387
    5. Mark A. Sussman
      Pages 389-405
  6. Back Matter
    Pages 421-431

About this book


The revolution in molecular medicine makes it imperative to integrate the classical and molecular approaches to drug development for the treatment of heart disease, the number one killer in North America and Europe. In the Cardiac Drug Development Guide, basic medical researchers, clinicians, and pharmacologists join forces to comprehensively survey the most recent breakthroughs in molecular cardiology and review the latest drug discoveries in cardiac and cardiovascular medicine. Topics range from novel molecular targets for cardiac drug development, to functional endpoints for evaluating cardiac drug activity, to clinical aspects of cardiovascular therapeutics. The authors describe the most advanced procedures in cardiovascular pharmacology, including in vivo and in vitro whole animal studies, the electrophysiological methods used to study pacemaker cells, and the application of biochemical principles and technologies to novel therapeutic agents. Also discussed are the methods used to express the ion channels involved in cardiovascular pharmacology, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics in cardiovascular drug development, gender differences in heart failure, and angiogenesis therapies for coronary heart disease. Each chapter concisely illustrates the concepts described and includes comprehensive background information, detailed figures and tables, and an up-to-date list of the most important references.
Comprehensive and easy-to-understand, the Cardiac Drug Development Guide offers pharmacologists, cardiologists, and physiologists not only a gold-standard survey of the many different methods being used to develop new heart drugs, but also details powerful new ways in which cardiovascular disease is targeted, from the whole organ to the genetic level.

Editors and affiliations

  • Michael K. Pugsley
    • 1
  1. 1.Department of PharmacologyForest Research InstituteJersey City

Bibliographic information

  • DOI
  • Copyright Information Humana Press 2003
  • Publisher Name Humana Press
  • eBook Packages Springer Protocols
  • Print ISBN 978-1-58829-097-7
  • Online ISBN 978-1-59259-404-7
  • Series Print ISSN 1557-2153
  • Series Online ISSN 1940-6053
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals